Shin Nippon Biomedical Laboratories, Ltd.
Records under this name other than the patents Shin Nippon Biomedical Laboratories, Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 23 patents it holds.
Back to Shin Nippon Biomedical Laboratories, Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,687,536 | Methods and Compositions for Intranasal Delivery Formerly held In force · High confidence | In force | High confidence | |
| US 9,617,547 | Chiral nucleic acid adjuvant Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,144,933 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,149,905 | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,322,173 | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,745,274 | Compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor Lapsed on the fee record Ended Aug 29, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 29, 2025 | USPTO record |
| US 7,638,138 | Compositions for nasal administration of pharmaceuticals Term ended Term ended Oct 30, 2023 · USPTO record | Term ended | Term ended Oct 30, 2023 | USPTO record |
| US 8,435,554 | Compositons for nasal administration of pharmaceuticals Term ended Term ended Apr 2, 2023 · USPTO record | Term ended | Term ended Apr 2, 2023 | USPTO record |
| US 9,138,410 | Compositions for nasal administration of pharmaceuticals Term ended Term ended Feb 21, 2023 · USPTO record | Term ended | Term ended Feb 21, 2023 | USPTO record |
| US 9,617,324 | Ameliorating agent for blood-brain barrier dysfunction Formerly held Lapsed on the fee record Ended Apr 11, 2021 · USPTO record | Lapsed on the fee record | Ended Apr 11, 2021 | USPTO record |